For research and educational purposes only. Not medical advice.
Somatropin Reference
Educational, not medical advice reference for Somatropin: GH Release, Hormonal; regulatory status, evidence posture, source review, and schedule…
Reference summary
Somatropin is a label-verified recombinant human growth hormone product family with decades of approved-label evidence in the listed indications. pepSmart surfaces label-reference content only and does not endorse off-label use.
Regulatory and posture
- Categories
- GH Release, Hormonal
- Aliases
- Recombinant human growth hormone, Genotropin, Humatrope, Norditropin, Saizen, Omnitrope, rhGH, HGH
- Evidence posture
- human - Prescription recombinant human growth hormone. WADA-prohibited under category S2 at all times. Distribution and possession outside an FDA-approved indication is illegal under the United States Anabolic Steroid Control Act. Counterfeit-product and black-market diversion risks are well documented.
- Regulatory status
- FDA-approved prescription medication (Genotropin, Humatrope, Norditropin, Saizen, Omnitrope, and similar). Indications include pediatric and adult growth hormone deficiency, Turner syndrome, chronic kidney disease pediatric short stature, idiopathic short stature, Prader-Willi syndrome, AIDS wasting, and short bowel syndrome - strictly per indication. WADA-prohibited under category S2 at all times. Possession or distribution outside an FDA-approved indication is restricted under the United States Anabolic Steroid Control Act.
- Content review status
- label verified
Selected public sources
- DailyMed somatropin (Genotropin, Humatrope, Norditropin, Saizen, Omnitrope) prescribing information
- WADA prohibited list and resources
Related tools
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.
- Protocol builder overview - Public overview of the Pro protocol builder.